FAST Scoring for Alzheimer's Dementia
The Functional Assessment Staging Tool (FAST) is a 16-stage scale (ranging from Stage 1 to Stage 7 with substages) that assesses functional decline in Alzheimer's disease by rating activities of daily living from normal functioning through severe dementia, with scores typically presented as stages rather than numerical totals. 1
Overview of FAST Structure
The FAST scale is based on the Global Deterioration Scale (GDS) and was specifically designed to track functional deterioration throughout the entire course of Alzheimer's disease, including the most severe stages 2, 3. It is administered by interviewing the care partner or the patient (if at a mild stage) and takes approximately 7-10 minutes to complete 1.
FAST Staging System
The scale progresses through these key stages:
Early Stages (1-3)
- Stage 1: No functional decline (normal adult)
- Stage 2: Very mild decline (subjective complaints of forgetting)
- Stage 3: Mild decline (early functional deficits in demanding situations)
Middle Stages (4-5)
- Stage 4: Moderate decline (requires assistance with complex tasks like managing finances, planning dinner parties)
- Stage 5: Moderately severe decline (requires assistance selecting proper clothing, may need prompting to bathe)
Late Stages (6-7)
- Stage 6: Severe decline (requires assistance with dressing, bathing, toileting; includes substages 6a-6e for specific ADL impairments)
- Stage 7: Very severe decline (progressive loss of speech, ambulatory ability, consciousness; includes substages 7a-7f tracking final functional losses)
Scoring Methodology
Items are rated on a 4-point scale: performs task normally (0), mild impairment (1), moderate impairment (2), or severe impairment (3) 1. The clinician identifies which stage best describes the patient's highest level of functional deficit. In typical Alzheimer's disease, patients progress through these stages in sequence, though atypical dementias may not follow this ordinal pattern 1.
Clinical Utility and Validation
The FAST has been extensively validated across multiple populations 4, 2:
- Strong correlations with cognitive measures: FAST correlates significantly with MMSE (r = -0.71), CDR, and other dementia severity scales 4
- Validated in both primary and specialty care settings and can be administered by clinical or non-clinical staff 1
- Particularly useful for severe dementia staging: Unlike many functional scales that lose sensitivity in advanced disease, FAST maintains utility through end-stage dementia 1, 2
- Prognostic value: Often used to determine preliminary eligibility for palliative or hospice care in patients with severe dementia 1
Important Clinical Caveats
The FAST is most accurate for typical Alzheimer's disease dementia 1. Atypical presentations or mixed dementias may not follow the expected sequential progression. When using FAST:
- Ensure you're assessing what the patient can actually do, not what they theoretically should be able to do
- Account for non-cognitive factors (sensory impairments, motor dysfunction) that may confound functional assessment
- Remember that FAST tracks IADLs and BADLs across the full spectrum, making it superior to scales like the FAQ that lose utility beyond mild-moderate stages 1
Recent evidence suggests FAST provides clinically meaningful severity estimates even when biomarkers are limited and can help overcome confounding factors in real-world functional assessment 5.